Search research articles
Contact Us
Filters
Showing results (21-30 of 47) with videos related to
Page
of 5
Sort By:
Frontiers in Oncology
|
June 13, 2022
Single-Cell Proteomics Analysis of Recurrent Low-Grade Serous Ovarian Carcinoma and Associated Brain Metastases
Tanja Pejovic, Pierre-Valérien Abate, Hongli Ma, et al.
Advances in Experimental Medicine and Biology
|
December 11, 2019
Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance
Marilyne Labrie, Yong Fang, Nicholas D Kendsersky, et al.
Cancer Research
|
November 29, 2018
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen, Wei Zhao, Zhenlin Ju, et al.
Oncotarget
|
November 7, 2015
Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin
Maria Claudia Vladoiu, Marilyne Labrie, Myriam Létourneau, et al.
Oncogene
|
March 26, 2025
Rictor orchestrates β-catenin/FOXO balance by maintaining redox homeostasis during development of ovarian cancer
Xuejiao Zhao, Huiling Lai, Guannan Li, et al.
Cold Spring Harbor Perspectives in Medicine
|
May 3, 2023
The Breast Cancer Proteome and Precision Oncology
Jonathan T Lei, Eric J Jaehnig, Hannah Smith, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 21, 2018
FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer
Huiling Lai, Xuejiao Zhao, Yu Qin, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
October 17, 2019
Correction to: FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer
Huiling Lai, Xuejiao Zhao, Yu Qin, et al.
NPJ Breast Cancer
|
May 10, 2022
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
Xuan Liu, Zhongqi Ge, Fei Yang, et al.
JCO Precision Oncology
|
July 12, 2021
Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer
Swapnil Parmar, Jamie M Keck, Ben Kong, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 47) with videos related to
Sort By:
Page
of 5
Frontiers in Oncology
|
June 13, 2022
Single-Cell Proteomics Analysis of Recurrent Low-Grade Serous Ovarian Carcinoma and Associated Brain Metastases
Tanja Pejovic, Pierre-Valérien Abate, Hongli Ma, et al.
Advances in Experimental Medicine and Biology
|
December 11, 2019
Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance
Marilyne Labrie, Yong Fang, Nicholas D Kendsersky, et al.
Cancer Research
|
November 29, 2018
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen, Wei Zhao, Zhenlin Ju, et al.
Oncotarget
|
November 7, 2015
Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin
Maria Claudia Vladoiu, Marilyne Labrie, Myriam Létourneau, et al.
Oncogene
|
March 26, 2025
Rictor orchestrates β-catenin/FOXO balance by maintaining redox homeostasis during development of ovarian cancer
Xuejiao Zhao, Huiling Lai, Guannan Li, et al.
Cold Spring Harbor Perspectives in Medicine
|
May 3, 2023
The Breast Cancer Proteome and Precision Oncology
Jonathan T Lei, Eric J Jaehnig, Hannah Smith, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
February 21, 2018
FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer
Huiling Lai, Xuejiao Zhao, Yu Qin, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
October 17, 2019
Correction to: FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer
Huiling Lai, Xuejiao Zhao, Yu Qin, et al.
NPJ Breast Cancer
|
May 10, 2022
Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers
Xuan Liu, Zhongqi Ge, Fei Yang, et al.
JCO Precision Oncology
|
July 12, 2021
Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer
Swapnil Parmar, Jamie M Keck, Ben Kong, et al.
Page
of 5